Last reviewed · How we verify
metronidazole and azithromycin
This combination uses metronidazole to disrupt bacterial DNA and azithromycin to inhibit bacterial protein synthesis, together targeting anaerobic and aerobic pathogens.
This combination uses metronidazole to disrupt bacterial DNA and azithromycin to inhibit bacterial protein synthesis, together targeting anaerobic and aerobic pathogens. Used for Polymicrobial infections including anaerobic and aerobic bacteria, Intra-abdominal infections, Pelvic inflammatory disease.
At a glance
| Generic name | metronidazole and azithromycin |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | Antibiotic combination |
| Target | Bacterial DNA (metronidazole); bacterial 50S ribosome (azithromycin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Metronidazole is a nitroimidazole that generates reactive oxygen species in anaerobic bacteria, damaging their DNA. Azithromycin is a macrolide antibiotic that binds to the bacterial 50S ribosomal subunit, inhibiting protein synthesis. Together, they provide broad-spectrum coverage against both anaerobic and aerobic bacteria, commonly used in polymicrobial infections.
Approved indications
- Polymicrobial infections including anaerobic and aerobic bacteria
- Intra-abdominal infections
- Pelvic inflammatory disease
- Aspiration pneumonia
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
- Metallic taste (metronidazole)
- QT prolongation (azithromycin)
- Photosensitivity
Key clinical trials
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD) (PHASE2)
- Effects of Probiotic in Treatment of Persistent Diarrhea in Children (NA)
- Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies (PHASE4)
- Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth (PHASE4)
- Flapless Surgical Treatment of Peri-implantitis
- Short-Term Use of Antibiotics and Adherence Level (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metronidazole and azithromycin CI brief — competitive landscape report
- metronidazole and azithromycin updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI